An interventional study of PRIDE QUIT and Enhanced Treatment As Usual (ETAU) in Smoking Cessation, Depression and Anxiety, sponsored by Massachusetts General Hospital. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Smoking Cessation by Massachusetts General Hospital — 4 open to participants now, 5 under way, none of them phase 3. Smoking Cessation · Massachusetts General Hospital.
Among the 27 studies in Smoking Cessation by Massachusetts General Hospital, this one is the 18th largest by planned enrollment, is one of 4 that started in 2024, is one of 15 with no phase, and was the 25th registered.
1,583 studies on the registry are indexed under Smoking Cessation; 196 are open to participants now.
Browse Smoking Cessation studies →4 of the 27 studies in Smoking Cessation by Massachusetts General Hospital are open now, in 2 countries. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18–65
Massachusetts General Hospital · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in South Africa
Ages 18+
By country, each count listing its studies:
Of the 134 Smoking Cessation studies recruiting now, 92 (69%) set no upper age limit and 35 (26%) stop at 75 or younger; 6 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 163 across 1,425 interventional studies indexed under Smoking Cessation.
Median enrollment 131 across the 27 interventional studies. Of the 22 that completed or were terminated, 16 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
3 of the studies in Smoking Cessation by Massachusetts General Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06654414Massachusetts General HospitalAdapting and Pilot Testing a Skills-based Smoking Cessation Intervention to Address Developmental and Health-related Stress Among Adults Who Smoke | 2027-03-31 |
| NCT05842161Massachusetts General HospitalSouth Africa Smoking Cessation and Engagement in HIV/TB Care Care | 2027-05-01 |
| NCT06678243Massachusetts General HospitalTesting the mHealth App Intervention for Nondaily Smokers "SiS4" | 2027-07-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 27 studies in Smoking Cessation by Massachusetts General Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Smoking remains the leading preventable cause of death in the United States, and there are persistent and significant disparities in tobacco use among transgender and gender diverse (TGD) individuals. Stigma, discrimination, gender dysphoria, and other gender minority stressors likely contribute to these disparities, and the increased burden of gender minority stress may also be driving higher prevalence rates of anxiety and depression, both of which are more common among TGD individuals and among those who smoke relative to comparison samples. This study will (1) explore the ways in which gender minority stressors and associated anxiety and depression compromise smoking cessation among TGD individuals, identifying elements in an existing smoking cessation intervention that need to be adjusted to meet their unique needs; (2) adapt an existing smoking cessation intervention for TGD individuals; and (3) evaluate the feasibility and acceptability of the adapted intervention in a pilot randomized controlled trial.
Despite the substantial decrease in smoking prevalence over the past 50 years, persistent and significant disparities in tobacco use remain among clinical and non-clinical populations of adults who smoke. Cigarette use among clinical populations, including patients with HIV and those with significant developmental stress, ranges from approximately 40-70%, compared with 10-12% among non-clinical populations. Clinical populations with HIV and developmental stressors also show dramatically higher rates of e-cigarette use relative to non-clinical populations (26.5% vs. 5.5% in some samples of adults who smoke). Adults managing HIV and developmental stressors may be particularly vulnerable to the consequences of tobacco use through increased heart disease risk, and smoking may hinder recovery from HIV and other related illnesses. Differential responses to developmental stressors, the stress of managing HIV and its treatment, and co-occurring clinical concerns such as anxiety and depression further contribute to these differences in tobacco use. Anxiety and depression are major impediments to smoking cessation and are more prevalent among people with developmental stress and people living with HIV than in non-clinical samples. Anxiety symptoms co-occur with smoking at high rates and significantly impair cessation success. Similarly, depressed mood and major depressive disorder-both more common among people who smoke than among those who do not-are associated with reduced odds of cessation. The high prevalence of anxiety and depression among clinical populations of adults who smoke therefore leaves these individuals particularly vulnerable to cessation difficulties. A tailored smoking cessation intervention that builds cognitive-behavioral skills for cessation while also reducing stress and associated anxiety and depression symptoms has strong potential to mitigate tobacco use. We propose to adapt an existing smoking cessation intervention, QUIT, to address the unique needs of adults with developmental stress who smoke. In focus groups with individuals who use tobacco (N ≤ 32) and providers (N ≤ 8), we will explore the ways in which stress and associated anxiety/depression compromise cessation, and identify content in the current version of QUIT that does and does not meet participants' needs. Providers will also comment on anticipated implementation barriers. Following the ADAPT-ITT model, these qualitative data will inform adaptation of the intervention. We will then test the feasibility and acceptability of the adapted intervention (QUIT 2.0) in a pilot randomized controlled trial (RCT; N = 60), assessing for signals of clinically meaningful change in biologically verified 7-day point-prevalence abstinence, average number of cigarettes smoked, and stress, anxiety, depression, and distress tolerance. If QUIT 2.0 is feasible and acceptable, it will be ready for a hybrid efficacy/effectiveness trial. We will also include a non-randomized, retrospective comparison group-matched on age, sex, and average number of cigarettes smoked per day in the past week-consisting of adults with HIV who completed the original, un-adapted intervention (QUIT 1.0).
The criteria were revised on the registry on Oct 8, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this adapted intervention arm (n=30) will receive empirically-based, Cognitive-Behavioral therapy-based strategies, tailored for transgender and gender diverse (TGD) individuals, which aims to help participants quit smoking and address gender minority stressors, anxiety, depression, and improve distress tolerance. This intervention group will receive a general educational session (session 0) followed by 5 active weekly sessions and a booster session 4 weeks after T2 (approx. 14 weeks post-baseline), with the quit day set between sessions 3 and 4.
Behavioral: PRIDE QUIT
Participants in this arm (n=30) will receive enhanced treatment as usual at Fenway Health. These participants will attend one session (brief counseling), will come to the clinic for weekly assessments only, and referral to the Quit Line.
Behavioral: Enhanced Treatment As Usual (ETAU)
This is an adapted behavioral intervention based on the integrated treatment for smoking cessation, anxiety, and depressed mood, known as QUIT, for persons with HIV. Through our treatment adaption process of QUIT (guided by Aim 1 and 2 data), PRIDE QUIT will be a Cognitive-Behavioral therapy-based intervention tailored for transgender and gender diverse (TGD) individuals, aimed at to helping participants quit smoking and address gender minority stressors, anxiety, depression, and improve distress tolerance. There will be three major assessments: baseline (T1), at the end of the intervention (T2), and a three-month follow-up visit (T3). This intervention group will receive a pre-randomization general educational session (session 0) followed by 5 weekly sessions and a booster sessions 4 weeks after T2, with the quit day set between sessions 3 and 4.
Brief counseling, American Cancer Society cessation resources (palm card with information on how to access the American Cancer Society website) after pre-randomization educational session (session 0,) the option of nicotine replacement therapy, and referral to the Quit Line.
Acceptability
Acceptability will be assessed via the Client Satisfaction Questionnaire-4 (CSQ-4) which will be completed after every other treatment session. Items are scored using a 4-point Likert scale with (1) quite dissatisfied; (2) dissatisfied; (3) satisfied; (4) quite satisfied. The questions include: (1) To what extent has our program met your needs?; (2) Have the services you received helped you to deal more effectively with your problems?; (3) In an overall, general sense, how satisfied are you with the service you have received?; (4) If you were to seek help again, would you come back to our program? The intervention will be deemed acceptable if at least 75% of the participants rate 4+ items on the acceptability questionnaires with a 3 or a 4 on the Likert-style scale.
Time frame: Through the end of treatment intervention, approximately 6 weeks
Feasibility of the Intervention
Feasibility of the intervention is a primary outcome measure that will be calculated based on three assessments: (1) interventionist fidelity to the protocol (via a review of 10% of session recordings to determine whether key themes were addressed), (2) session attendance, and (3) participant retention at follow-up. Feasibility will be demonstrated if at least (1) 80% of the reviewed sessions address all key themes, (2) 75% of the participants attend at least half of all treatment sessions; and (3) 70% of the participants complete the 3-month follow-up.
Time frame: Through participants' enrollment, approximately 6 months
7-Day Point Prevalence Abstinence
7-day point prevalence abstinence will be verified via expired-air carbon monoxide (CO) assessed with a Smokerlyzer, with 5ppm indicating abstinence (24 hours to two weeks). Because CO expired-air readings are significantly lower among users of e-cigarettes, abstinence for those using mostly e-cigarettes at baseline will be verified by cotinine assessment via a NicConfirm Mouth Swab Cotinine test (30 ng/ml indicates abstinence of 1-4 days).
Time frame: At the 3-month follow-up and 6-month follow-up
Gender Minority Stress
Gender minority stress will be measured via the internal experience subscales of the Gender Minority Stress and Resilience Measure (GMSRM), including non-affirmation of gender identity, internalized transphobia, negative expectations, nondisclosure, community connectedness, and pride. Participants respond to each statement using a five-point Likert scale ranging from "Strongly Disagree" to "Strongly Agree."
Time frame: At baseline assessment, 3-month follow-up, and 6-month follow-up
Average Number of Cigarettes Smoked Per Day in the Past Week
Average number of cigarettes smoked per day in the past week, assessed via self-report.
Time frame: At baseline assessment, end of each treatment session (weekly for 5 weeks post-baseline), 3-month follow-up, and 6-month follow up
Anxiety Symptoms
1\. Anxiety symptoms will be assessed by the Generalized Anxiety Disorder 7-item (GAD-7). Likert style: Not at all (0) to Nearly every day (3); scores range from 0 to 21, with higher scores indicating greater levels of symptomatology. 2. Participants will also be asked to rate their anxiety on a scale from 0 to 10, with 0 being no anxiety and 10 being the worst possible anxiety.
Time frame: (1) At baseline assessment, 3-month follow-up, and 6-month follow-up. (2) At baseline assessment, after each intervention session, 3-month follow-up, and 6-month follow-up
Depression Symptoms
1\. Depressive symptoms will be assessed by the Patient Health Questionnaire 8-item scale (PHQ-8). Likert style: Not at all (0) to Nearly every day (3); scores range from 0 to 24, with higher scores indicating greater levels of symptomatology. 2. Participants will also be asked to rate their depressive symptoms on a scale from 0 to 10, with 0 being no depressed mood and 10 being the worst possible depressed mood.
Time frame: (1) At baseline assessment, 3-month follow-up, and 6-month follow-up. (2) At baseline assessment, after each intervention session, 3-month follow-up, and 6-month follow-up.
Distress Tolerance
Distress tolerance will be assessed using the Distress Tolerance Scale (DTS). Likert style: Strongly Agree (1) to Strongly Disagree (5); scores range from 16-80, with higher scores indicating greater levels of distress tolerance.
Time frame: At baseline assessment, 3-month follow-up, and 6-month follow-up
Not enrolling at this site.
Not enrolling at this site.
Plan to share: Yes — Based on the approved DSMP, we plan to only share deidentified data via a controlled access repository. No PHI, recordings, or unconsented human data will be made available to other investigators.
Supporting information: Study protocol, Statistical analysis plan
Time frame: According to the approved DSMP, data will be uploaded at 6-monthly intervals.
Access criteria: Any shared data will be stored in the NIH-approved controlled access repository, Cancer Data Service (CDS). Other qualified investigators, with authorized CDS access will have access to this data.
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for Mar 2027, 30 months after the start.
Of 547 non-industry interventional studies with no phase under Smoking Cessation, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 30 months is above that.
Counting every sponsor, half of 564 studies reached it within 24 months; a quarter within 12 and three quarters within 44.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Mar 2025 → Mar 2027 and completion Mar 2025 → Aug 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →